A clinical trial investigating the possibility of using SV2A-PET as a marker of synaptic density in progressive MS compared to relapsing-remitting MS (RRMS) and healthy controls is underway, and is the first to gauge SV2A’s tie to MS patients (ClinicalTrials.gov ID–NCT04634994). This evidence concerns the gene SV2A and myeloid sarcoma.